# Exo Lab Italia S.R.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exo-lab-italia-s-r-l

- Industry: Biotechnology
- Headquarters: Pescara, Italy
- Website: www.exolabitalia.net
- Total disclosed funding: $5.3M
- Latest round: Series A (Feb 18, 2025)
- Investors on record: 5

## About

Exo Lab Italia S.R.L. is an innovative company focused on developing plant-derived exosomes for applications in cosmetics, dietary supplements, and pharmaceuticals, enhancing the delivery of therapeutic molecules.Founded in 2020 in Pescara, Italy, Exo Lab Italia S.R.L. specializes in the production of plant-derived exosomes. The company has raised EUR 5 million in a Series A funding round, which will bolster its production and research capabilities. The founder, whose history includes previous entrepreneurial ventures, has led the company through its initial stages, establishing its presence in the biotech sector.Exolab Italia specializes in the development and provision of plant-derived exosomes, utilized across sectors including cosmetics, dietary supplements, and pharmaceuticals. Their offerings enhance skin absorption and bioavailability, facilitating therapeutic molecule delivery. The cosmetics line improves skin regeneration, while supplements maximize nutrient absorption through overcoming gastric barriers. The company caters to clients in Europe, North America, and parts of Asia, positioning itself as a pioneer in pharmaceutical nanotechnology.Exolab Italia generates revenue through B2B partnerships and direct sales of its flagship products, including the Exo Elixir® range with formulations such as Alpine Rose and Camellia Sinensis. Sales typically involve wholesalers and retailers purchasing bulk quantities for resale. The company also partners with research institutions and pharmaceutical firms, establishing pricing based on proprietary formulations and benefits, reflecting its commitment to high-quality solutions in plant-derived exosomes.In February 2025, Exo Lab Italia S.R.L. raised EUR 5 million in Series A funding from investors including DSM-firmenich, CDP Venture Capital, and others. This funding will be utilized to expand production capacity and support advanced research projects, with plans to launch new products aimed at further enhancing therapeutic applications. The company is also targeting expansion into new geographic markets, focusing on increased presence in Asia and North America by 2026.

## Funding rounds

- Series A, Feb 18, 2025, $5.3M — CDP Venture Capital, Riello Investimenti, Maia Wealth, Scientifica Venture Capital, DSM-firmenich

## Investors

- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A
- Riello Investimenti (https://capitalatlas.ai/funds/riello-investimenti) — Series A
- Maia Wealth — Series A
- Scientifica Venture Capital (https://capitalatlas.ai/funds/scientifica-venture-capital) — Series A
- DSM-firmenich — Series A